SEC Form 4 · accession 0002050172-26-000036
Maze Therapeutics, Inc. · MAZE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harold Bernstein
Officer — President, R&D & CMO
Period of report
Sep 4, 2026
Accepted (ET)
Sep 8, 2026 · 4:20 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001842295
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 4, 2026 | S | 9,705 | $26.2238 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.42 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.